Events2Join

FDA rejects Public Citizen's Crestor petition


FDA rejects Public Citizen's Crestor petition - PharmaTimes

AstraZeneca says that the US Food and Drug Administration has formally rejected Public Citizen's petition to remove the Anglo-Swedish ...

Petition to Ban Cholesterol-Lowering Drug Rosuvastatin (Crestor)

Public Citizen, representing 160,000 consumers nationwide, hereby petitions the U.S. Food and Drug Administration (FDA) pursuant to the Federal Food, Drug ...

FDA rejects Public Citizen's Crestor petition - MM+M - Medical ...

The FDA said yesterday that Crestor does not pose a greater health risk than other statins, rejecting a petition from the consumer group Public Citizen to ...

FINDINGS - The Washington Post

The group, Public Citizen, had argued Crestor ... "Patient safety is our top priority and the FDA's rejection of Public Citizen's petition ...

Statement Regarding the FDA's Decision to Leave Rosuvastatin ...

On page 16 of its response to Public Citizen's petition to ban Crestor, the agency admits that although “estimates of the reporting rate ...

FDA Rejects Bid to Ban AstraZeneca's Crestor - TheStreet

... Crestor manufactured by. AstraZeneca. (AZN) . The agency turned down the request from Public Citizen, a longtime critic of the drug that has alleged that ...

FDA Rejects Bid to Ban Cholesterol Drug | Fox News

The FDA said it was rejecting a petition from drug industry watchdog Public Citizen (search) because there was no evidence that Crestor was any more ...

FDA REJECTS PETITION TO BAN SALE OF CHOLESTEROL DRUG ...

... rejected a petition to remove the cholesterol drug Crestor from the market. Dr. Sidney M. Wolfe of the consumer group Public Citizen had petitioned the ...

FDA Rejects Public Citizen's Petition for AstraZeneca's CRESTOR ...

AstraZeneca recently announced that the U.S. Food and Drug Administration (FDA) has formally denied Public Citizen's Health Research Group's (HRG) petition ...

FDA Rejects Request to Ban Cholesterol Drug | wfmynews2.com

A doctor with the consumer group Public Citizen petitioned the agency to ban Crestor -- citing reports of muscle toxicity and kidney damage. But the FDA says a ...

AstraZeneca loses court battle to prevent generic versions of Crestor

... Crestor in the US market. The FDA, meanwhile, rejected a citizen's petition filed by AstraZeneca seeking to halt generics. STAT+ Exclusive ...

Public Citizen's Wolfe Still Needling FDA | MedPage Today

He points to individual drugs like celecoxib (Celebrex), rosuvastatin (Crestor), or lorcaserin (Belviq) that Public Citizen pushed against ...

FDA Issues Response to Citizen Petitions Related to CBD

The US Food and Drug Administration (FDA) denied the requests in three citizen petitions, from the Consumer Healthcare Products Association (CHPA), the Council ...

FDA ORDERS ASTRAZENECA CRESTOR ADS PULLED - Ad Age

"Patient safety is our top priority and the FDA's rejection of Public Citizen's petition should reassure the millions of people who have ...

Public Citizen - The New York Times

Food and Drug Administration rejects calls by consumer group Public Citizen to withdraw drug Crestor ... F.D.A. Calls Ads for Cholesterol Pill Crestor ...

Should rosuvastatin be withdrawn from the market? - The Lancet

Public Citizen's Health Research Group, 1600 20th Street Northwest ... 3. Wolfe, SM. Dangers of rosuvastatin identified before and after FDA approval.

Crestor Lawsuits | Injuries, Misleading Ads and Settlements

The FDA asked AstraZeneca to stop running the ads. At the same time, the agency rejected the Public Citizen petition to recall Crestor. Researchers Tie ...

Dismiss public citizen petition on Crestor, Astrazeneca to US FDA

AstraZeneca, in its response sent to the US FDA, stated that Public Citizen's Health Research Group's (HRG) petition to remove Crestor (rosuvastatin calcium) ...

Correspondence - The Lancet

Petition to the FDA to remove the cholesterol-lowering drug rosuvastatin. (Crestor) from the market. http://www. citizen.org/publications/ ...

Rosuvastatin: An Independent Analysis of Risks and Benefits - PMC

[1] These concerns were expressed in a Public Citizen petition to the FDA on March 4, 2004 calling for its removal from the market. That petition was denied ...